other material
confidence high
sentiment positive
materiality 0.85
Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR
Cellectar Biosciences, Inc.
- CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.
- ORR of 80% and disease control rate 98.2% in heavily pre-treated WM patients (median 4 prior therapies).
- 78% of major responders progression-free at 18 months; median DoR not reached.
- Company plans to submit NDA in Q4 2024 and seek priority review.
- Preliminary cash and equivalents ~$25.9M as of June 30, 2024 (unaudited, subject to change).